Promising Nanotechnology Stocks To Keep An Eye On - July 30th

Key Points

• MarketBeat highlighted seven nanotechnology stocks, including Onto Innovation and OSI Systems, which have been experiencing significant trading volumes recently.
• Nanotechnology investments offer potential breakthroughs in various fields such as electronics, medicine, and energy by harnessing materials and innovations at the nanoscale.
• Companies mentioned are involved in diverse sectors with unique technologies, from spintronics at NVE Corporation to additive manufacturing with Nano Dimension, indicating the broad applications of nanotechnology.

Onto Innovation, OSI Systems, NVE, Nano Dimension, Clene, Biodexa Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of publicly traded companies whose core business involves the research, development or commercialization of materials, devices and systems engineered at the nanoscale (one billionth of a meter). Investing in these equities offers exposure to potential breakthroughs in fields such as electronics, medicine, energy and advanced materials driven by nanoscale innovations. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

Onto Innovation (ONTO)

Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology. The company offers lithography systems and process control analytical software. It also offers process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements.

ONTO traded up $2.22 on Wednesday, hitting $103.14. 524,326 shares of the company traded hands, compared to its average volume of 1,210,573. The company has a 50 day moving average of $97.93 and a 200-day moving average of $129.45. The stock has a market capitalization of $5.04 billion, a PE ratio of 23.31, a PEG ratio of 0.66 and a beta of 1.45. Onto Innovation has a 12-month low of $85.88 and a 12-month high of $228.42.

Read Our Latest Research Report on ONTO

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

NASDAQ OSIS traded up $1.99 on Wednesday, hitting $227.21. 66,151 shares of the company's stock were exchanged, compared to its average volume of 225,589. The firm's 50-day moving average price is $222.87 and its two-hundred day moving average price is $206.39. The firm has a market cap of $3.81 billion, a price-to-earnings ratio of 27.59, a P/E/G ratio of 1.89 and a beta of 1.27. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.11 and a quick ratio of 1.38. OSI Systems has a fifty-two week low of $129.18 and a fifty-two week high of $241.64.

Read Our Latest Research Report on OSIS

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Shares of NVE stock traded down $0.24 during trading on Wednesday, hitting $64.00. 19,084 shares of the company were exchanged, compared to its average volume of 43,210. NVE has a fifty-two week low of $51.50 and a fifty-two week high of $89.98. The stock has a market capitalization of $309.76 million, a price-to-earnings ratio of 21.33 and a beta of 1.15. The firm has a 50 day moving average price of $73.17 and a 200 day moving average price of $69.12.

Read Our Latest Research Report on NVEC

Nano Dimension (NNDM)

Nano Dimension Ltd., together with its subsidiaries, engages in additive manufacturing solutions in Israel and internationally. The company offers 3D printers, comprising AME systems, which are inkjet printers, that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; micro additive manufacturing systems, a digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and industrial additive manufacturing systems, that utilizes a patented foil system that fabricates ceramic and metal parts.

Shares of Nano Dimension stock traded up $0.02 during trading on Wednesday, hitting $1.42. 825,172 shares of the company were exchanged, compared to its average volume of 2,094,751. The stock has a market capitalization of $307.45 million, a price-to-earnings ratio of -3.54 and a beta of 1.13. Nano Dimension has a fifty-two week low of $1.34 and a fifty-two week high of $2.74. The firm has a 50 day moving average price of $1.52 and a 200 day moving average price of $1.81.

Read Our Latest Research Report on NNDM

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNN stock traded up $0.17 during midday trading on Wednesday, hitting $3.53. The stock had a trading volume of 61,568 shares, compared to its average volume of 71,069. The firm has a market cap of $29.19 million, a PE ratio of -0.87 and a beta of 0.55. Clene has a 12-month low of $2.28 and a 12-month high of $6.96. The company's 50-day moving average price is $3.75 and its 200 day moving average price is $3.79.

Read Our Latest Research Report on CLNN

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

NASDAQ:BDRX traded down $0.00 during trading hours on Wednesday, reaching $0.86. 161,457 shares of the company were exchanged, compared to its average volume of 1,957,086. The stock has a 50 day simple moving average of $0.99 and a 200 day simple moving average of $2.06. Biodexa Pharmaceuticals has a 52-week low of $0.78 and a 52-week high of $17.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.75 and a current ratio of 1.75.

Read Our Latest Research Report on BDRX

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNNW stock traded down $0.01 during mid-day trading on Wednesday, reaching $0.03. The company's stock had a trading volume of 5,200 shares, compared to its average volume of 10,821. The company's 50 day simple moving average is $0.03 and its 200-day simple moving average is $0.03. Clene has a 12-month low of $0.02 and a 12-month high of $0.08.

Read Our Latest Research Report on CLNNW